Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective

被引：0

|

作者：

Kenneth Boyd

Peter Hall

机构：

来源：

PharmacoEconomics | 2016年 / 34卷

关键词：

Everolimus; Moral Responsibility; Pertuzumab; Judicial Review; Eribulin;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：529 / 531

页数：2

相关论文

共 50 条

[41] Marmot says government can't afford to ignore health inequality
Mooney, Helen
BRITISH MEDICAL JOURNAL, 2010, 340
[42] What will it cost and can we afford it?
Anderson, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
[43] Europe Can Afford the Cost of Autonomy
Heisbourg, Francois
SURVIVAL, 2021, 63 (01) : 25 - 32
[44] Budget impact and cost-effectiveness: can we afford precision medicine in oncology?
Doble, Brett
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2016, 76 : S6 - S11
[45] Advancing health disparities research -: Can we afford to ignore measurement issues?
Stewart, AL
Nápoles-Springer, AM
MEDICAL CARE, 2003, 41 (11) : 1207 - 1220
[46] Architects can't afford to ignore 3D any longer
Porter, SM
COMPUTER GRAPHICS WORLD, 1997, 20 (06) : 4 - 4
[47] US PLC software providers can't afford to ignore safety standards
Geiger, M
I&CS-INSTRUMENTATION & CONTROL SYSTEMS, 1998, 71 (04): : 67 - 68
[48] High-dose riboflavin for the prevention of migraine: can we afford to ignore it?
Davis, JS
INTERNAL MEDICINE JOURNAL, 2004, 34 (06) : 372 - 372
[49] PRODUCT LIABILITY - A GRIM REALITY YOU CAN NO LONGER AFFORD TO IGNORE.
Stanton, Warren
EDN, 1977, 22 (08) : 115 - 118
[50] Bibliometric awareness in nursing scholarship: Can we afford to ignore it any longer?
Smith, Derek R.
Hazelton, Michael
NURSING & HEALTH SCIENCES, 2011, 13 (04) : 384 - 387

← 1 2 3 4 5 →